Hengrui Medicine Subsidiaries Get Clinical Trial Approval for Two Drugs

Hengrui Medicine announced on August 4, 2026, that its subsidiaries Suzhou Shengdiya Biopharmaceutical Co. , Ltd. and Shanghai Shengdi Pharmaceutical Co. received the Drug Clinical Trial Approval Notices issued by the National Medical Products Administration for SHR-A2009 injection and Adebrelimab injection. The company will conduct the relevant clinical trials in the near term.